Evidence map›Paper›PMID 22886699›Full record

ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2013

Hexa-D-arginine treatment increases 7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype.

Baozhi Yuan, Jian Q Feng, Stephen Bowman, Ying Liu, Robert D Blank, Iris Lindberg, Marc K Drezner

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Review
  3. Development and Prospects of Furin Inhibitors for Therapeutic Applications.International journal of molecular sciences · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. PHEXGenes · 2022
    Article
  8. Article
  9. The regulation of FGF23 under physiological and pathophysiological conditions.Pflugers Archiv : European journal of physiology · 2022
    Review
  10. The Causes of Hypo- and Hyperphosphatemia in Humans.Calcified tissue international · 2021
    Review
  11. Upstream Regulators of Fibroblast Growth Factor 23.Frontiers in endocrinology · 2021
    Review
  12. Review
  13. Mechanisms of phosphate transport.Nature reviews. Nephrology · 2019
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Family with sequence similarity member 20C is the primary but not the only kinase for the small-integrin-binding ligand N-linked glycoproteins in bone.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016
    Article
  20. Review
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Baozhi YuanDepartment of Medicine, University of Wisconsin-Madison and Geriatric Research and Education Center, William S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
Jian Q Feng
Stephen Bowman
Ying Liu
Robert D Blank
Iris Lindberg
Marc K Drezner
University of Wisconsin–Madison · USTexas A&M Health Science Center · USUniversity of Maryland, Baltimore · USWilliam S. Middleton Memorial Veterans Hospital · US

Funding

Institutional Clinical and Translational Science AwardUL1TR000427 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2012 to 2016
$32.2M
INSTITUTIONAL CTSA (UW-MADISON): CLINICAL TRIALSUL1RR025011 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2007 to 2011
$29.5M
CONTROL OF PEPTIDE HORMONE BIOSYNTHESIS BY PC2 AND 7B2R01DK049703 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI LINDBERG, IRIS · 1996 to 2012
$3.7M
PATHOGENESIS OF VITAMIN D REFRACTORY DISEASESR01AR027032 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 1986 to 2015
$3.5M
DMP1 Mutations: Defects in OdontogenesisR01DE018486 · NIDCR · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI FENG, JIAN Q. · 2008 to 2012
$1.7M
Congenic Mouse Strains Harboring Bone Strength Quantitative Trait LociR01AR054753 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI BLANK, ROBERT DANIEL · 2009 to 2013
$1.6M
PATHOGENESIS Of VITAMIN D REFRACTORY DISEASESR56AR027032 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2009 to 2009
$378k
NCATS NIH HHS UL1 TR000427NCRR NIH HHS 1UL1RR025011NCRR NIH HHS UL1 RR025011NIAMS NIH HHS AR54753NIAMS NIH HHS R01 AR027032NIAMS NIH HHS R01 AR054753NIAMS NIH HHS R01-AR27032NIAMS NIH HHS R56 AR027032NIDCR NIH HHS R01 DE018486NIDCR NIH HHS R01-DE018486NIDDK NIH HHS DK049703NIDDK NIH HHS R01 DK049703PHS HHS R01-SK65830
6 · The paper itself

Abstract

Inactivating mutations of the "phosphate regulating gene with homologies to endopeptidases on the X chromosome" (PHEX/Phex) underlie disease in patients with X-linked hypophosphatemia (XLH) and the hyp-mouse, a murine homologue of the human disorder. Although increased serum fibroblast growth factor 23 (FGF-23) underlies the HYP phenotype, the mechanism(s) by which PHEX mutations inhibit FGF-23 degradation and/or enhance production remains unknown. Here we show that treatment of wild-type mice with the proprotein convertase (PC) inhibitor, decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone (Dec), increases serum FGF-23 and produces the HYP phenotype. Because PC2 is uniquely colocalized with PHEX in osteoblasts/bone, we examined if PC2 regulates PHEX-dependent FGF-23 cleavage and production. Transfection of murine osteoblasts with PC2 and its chaperone protein 7B2 cleaved FGF-23, whereas Signe1 (7B2) RNA interference (RNAi) transfection, which limited 7B2 protein production, decreased FGF-23 degradation and increased Fgf-23 mRNA and protein. The mechanism by which decreased 7B2•PC2 activity influences Fgf-23 mRNA was linked to reduced conversion of the precursor to bone morphogenetic protein 1 (proBMP1) to active BMP1, which resulted in limited cleavage of dentin matrix acidic phosphoprotein 1 (DMP1), and consequent increased Fgf-23 mRNA. The significance of decreased 7B2•PC2 activity in XLH was confirmed by studies of hyp-mouse bone, which revealed significantly decreased Sgne1 (7B2) mRNA and 7B2 protein, and limited cleavage of proPC2 to active PC2. The expected downstream effects of these changes included decreased FGF-23 cleavage and increased FGF-23 synthesis, secondary to decreased BMP1-mediated degradation of DMP1. Subsequent Hexa-D-Arginine treatment of hyp-mice enhanced bone 7B2•PC2 activity, normalized FGF-23 degradation and production, and rescued the HYP phenotype. These data suggest that decreased PHEX-dependent 7B2•PC2 activity is central to the pathogenesis of XLH.

Indexed as

Genetic Diseases, X-LinkedAnimalsBone and BonesExtracellular Matrix ProteinsFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGene Expression RegulationHumansMaleMiceMice, Inbred C57BLMice, Mutant StrainsNeuroendocrine Secretory Protein 7B2OligopeptidesDmp1 protein, mouseExtracellular Matrix ProteinsFGF23 protein, humanFgf23 protein, mouseFibroblast Growth Factor-23Fibroblast Growth Factorshexaarginine amideNeuroendocrine Secretory Protein 7B2OligopeptidesPcsk2 protein, mouseProprotein Convertase 2RNA, MessengerSgne1 protein, mouse

Identifiers

PMID22886699
PMCPMC3523095
OpenAlexW2068151850

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.